HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon management

This article was originally published in The Rose Sheet

Executive Summary

Avon President and Chief Operating Officer Susan Kropf will retire after 35 years with the company, direct-seller says March 9. Exec will step down from her position effective July 1 and will officially retire at the end of the year. Her successor will not be named, "in line with the company's new global operating structure," Avon notes. Firm unveiled reorganization plan, which includes senior management realignment, during a November strategy meeting (1"The Rose Sheet" Nov. 21, 2005, p. 3). Going forward, "All business units and support functions will report directly" to CEO Andrea Jung, Avon says. Kropf was appointed president and Chief Operating Officer in 2001 (2"The Rose Sheet" Jan. 22, 2001, In Brief). Prior to that, she was exec VP and Chief Operating Officer, Avon North America and Global Business Operations...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel